Abstract. Carbapenem-resistant Pseudomonas aeruginosa (CRPA), a World Health Organization high-priority pathogen, represents a major clinical threat due to

A multidrug-resistant fungus is causing life-threatening heart infections in hospitalised patients. Candida auris endocarditis is rare but serious—a… #Candidaauris #Endocarditis #Fungalinfection #InfectiousDisease #Multidrugresistance

A rising epidemic of multidrug-resistant (MDR) tuberculosis in Russia is being fuelled in part by infection among inmates in Russia's crowded jail system, and also by what one public health expert cal...

The study authors say the results do not negate the importance of hand hygiene.

Ceftazidime-avibactam therapy yields a high clinical response rate in patients with MDR Gram-negative pneumonia in routine practice.

When antibiotics failed an 11-year-old beluga whale with stubborn pneumonia, her veterinarians reached for something that sounds, at first, counterintuitive: viruses. Jetta, a beluga at Mystic Aquarium in Connecticut, had developed chronic pneumonia caused by a multidrug-resistant strain of E. coli. Powerful antibiotics had done little to clear the infection. So veterinarians at the aquarium, working with researchers at the University of Florida, selected bacteriophages—viruses that prey specifically on bacteria—capable of attacking the strain infecting her. But how do you get virus-based medicine deep into the lungs of a whale? Their answer was a custom nebulizer built for a blowhole. Caretakers taught Jetta to swim to the edge of her pool three times a day and inhale deeply through the device, breathing in a mist containing the phages. More than a year after treatment, her care team says it has found no evidence that the pneumonia has returned and no apparent adverse effects from the therapy. The treatment appears to represent the first use of bacteriophage therapy against a bacterial infection in a marine mammal via nebulizer. Given the odd case, it’s no surprise this is a world-first operation. But the case has not yet been described in a peer-reviewed...

Campylobacter spp. remain the leading bacterial cause of foodborne gastroenteritis in Western countries. We report sustained, previously unrecognized circulation of a multidrug-resistant Campylobacter coli sequence type 10042 lineage across Europe during 2018–2025. Whole-genome sequencing of 217 isolates from 9 countries spanning human, animal, food, and environmental sources identified cross-border clusters, including a large lineage linking primarily Portugal and Luxembourg, as well as Germany, Ireland, Spain, and the United Kingdom. Genomic data indicates ongoing clonal expansion with increasing diversification over time. Isolates exhibited a conserved multidrug-resistant phenotype, including resistance to fluoroquinolones, tetracyclines, and β-lactams; reduced susceptibility to carbapenems was observed. Resistance was associated with GyrA Thr86Ile, tet(O/32/O)/tet(O) genes, and blaOXA-61 promoter variants; variation in porA was linked to variable amoxicillin/clavulanic acid and ertapenem susceptibility. Those findings demonstrate that C. coli infections can involve sustained international transmission rather than sporadic cases and highlight the need for coordinated, cross-sector genomic surveillance to detect emerging antimicrobial-resistant lineages.

Salmonella enterica subspecies enterica serovar Infantis carrying the blaCTX-M-65 gene has been increasingly detected globally, including in South Korea, since 2022. We analyzed 65 blaCTX-M-65–positive Salmonella Infantis isolates from humans, poultry, and wastewater collected during 2022–2024 by using whole-genome sequencing and phylogenomic analysis. All isolates were multidrug resistant, commonly to aminoglycosides, β-lactams, quinolones, tetracyclines, amphenicols, and folate pathway inhibitors. Phylogenetic analysis revealed high genetic similarity among isolates from humans, poultry, and wastewater, which were intermingled within monophyletic clades with high bootstrap support, indicating close genomic relatedness across sectors. Bayesian phylogeographic reconstruction suggested multiple potential introductions during 2018–2022, including 1 lineage related to isolates from the United States (clade I) and others related to isolates from the United Kingdom (clade II). Those findings highlight the emergence and genomic diversity of blaCTX-M-65–positive Salmonella Infantis in South Korea and support the value of continued genomic surveillance across sectors.

The emerging fungus, <em>C. auris </em>can cause severe multidrug-resistant illness in hospitalized patients.

A new study has identified a promising strategy to tackle antimicrobial resistance by making multidrug-resistant bacteria more vulnerable to existing antibiotics, potentially allowing doctors to…

Empiric antibiotic selection for complicated urinary tract infections is increasingly complex due to the rising prevalence of multidrug-resistant organisms. We conducted a network meta-analysis to compare clinical efficacy and safety among existing empiric treatment options.MethodsWe performed a frequentist random-effects network meta-analysis of randomized controlled trials evaluating single-agent empiric regimens for adults with complicated urinary tract infections. The primary endpoints were clinical response, microbiological response, and serious adverse events. Ceftriaxone served as the common comparator.ResultsForty-seven trials were identified through a systematic search. In the primary analysis of 17 studies published after the year 2000, evaluating agents currently accessible in the United States, in which baseline ceftriaxone non-susceptibility among Enterobacterales averaged approximately 15%. Ceftriaxone demonstrated clinical response rates comparable to broader-spectrum alternatives. Although some agents achieved higher microbiological eradication, these differences did not translate into superior clinical cure rates. Safety profiles were stable across antibiotic classes, with no significant differences in serious adverse events compared to cephalosporins.ConclusionsCeftriaxone remains an effective empiric option for hemodynamically stable adults with complicated urinary tract infections, in settings with comparable resistance prevalence. These findings provide evidence to support antimicrobial stewardship efforts that prioritize narrower-spectrum agents, preserving broader-spectrum therapies for patients at highest risk for resistant pathogens.

AbstractCandida auris is an emerging, multidrug-resistant fungal pathogen of growing concern in solid organ transplantation, where colonization may have implications for pretransplant candidacy and post-transplant outcomes. Although C. auris screening is increasingly common in presurgical and critical care settings, no national or professional guidelines in the United States specify who, how, or when to screen, nor is there consensus on how screening results should impact patient care. Here, we examine the ethical significance of C. auris colonization in transplant candidacy decisions and outline the arguments for and against universal C. auris screening of solid organ recipients in the peritransplant period. We propose risk-based screening as a middle-ground approach for hospitals and physicians seeking to develop value-informed, evidence-based guidelines at a time when data are still emerging and evolving. Ultimately, the fundamental goal of pretransplant screening is harm reduction through preparedness and individualized risk assessment, not a proxy for institutional risk tolerance or an artifact of how a screening policy is applied.